Summary: Warns against chasing LUNR at current highs; imminent capital raise/dilution makes near-term risk skewed down.

structural marker; pre-classified as canonical yfinance ticker

$LUNR $9.25+ rn - Chances are they will do a capital raise so time to lock your ~300% quick gains. In LT stock will do very well but dilution is imminent before year end so be careful chasing here imo
#SupDup


Summary: Bullish SMCI: Hindenburg short report mostly unfounded fluff; imminent 10-K filing expected with no material changes, validating the long.

$SMCI $481+ rn - Delayed 10k filing should happen any day within a couple of days and as mgmt had stated there will be NO material changes so lets see.
Hindenburg was full of mostly fluff. I told you all it was their classic scare tactic mostly BS after having shorted stocks with a few things correct but that would be the case with most publicly traded companies anywhere in the world imo 👇
#SupDup

$SMCI $SMCI:CA - Super Micro Computer: Most Arguments In The Short Report Are Unfounded. https://t.co/5oxbygp753 #stocks #stockmarket #markets


Summary: Long CING targeting $10–$20 within 2 years; buying dips as near- and long-term investment.

$CING $3.10 - $3.25 - Loading on dips as I see stock rising to between $10 - $20 within next 2 years. This is a great NT & LT buy for investors with patience imo.
#SupDup


Summary: Added to CING position under $6 for both near-term and long-term holds.

$CING <$6 - Added more for NT & LT
#SupDup


Summary: Plans to add to ALLR position on further dips to lower cost average; wants more selling pressure first.

@TonyAC795453 @AAllh4527 @0239targ Feel the same as I have a day or two ago. I want more shorting to happen so it goes lower further. I am going to add more at some point if it dips further to cost avg.

@SuperDuperInvst @AAllh4527 @0239targ How do you see ALLR today???


Summary: Long KPRX at $3.50 as golden buying opportunity; trades below $30M cash, multiple analyst Buy ratings, $300M+ deal with Thea TOI, and multi-billion dollar drug pipeline potential.

$KPRX $3.50 - GOLDEN BUYING OPPORTUNITY for LT investors. Read below to see why I say so.
Current Value: ~$10 mln, 3x Cash on hand of ~$30 mln (Expected runway into 2027)
Equity float: 1.36 mln shares

Buy rating with $54 PT by Ladenburg Thalmann
Buy rating with $27 PT by Maxim Group
Buy rating with $10 PT by HC Wainwright

Kiora Pharmaceuticals, Inc. progressing drug developments for Retinal Diseases to Slow/Stop vision loss or Restore lost Eye Vision  👀

$300+ mln potential deal in place with upto 20% royalties on sales for one of its development drug KIO-301 with European Ophthalmic giant Thea TOI (Excluding Asia rights). Thea TOI paying quarterly for drug development/other milestone payments.  KI0-104 Worldwide rights still owned by Kiora. Company is exploring licensing/strategic  partnerships)
Huge multi billion dollars USA & Global sales opportunities upon approval of drugs imo.
#SupDup @BillAckman @CathieDWood


Summary: Disputes slowing-demand narrative; all six names are at the start of a long-lasting AI/ML hardware and software era.

$NVDA $SMCI $AAOI $AMD $DELL $HPQ
Don't let these analysts fool you by saying demand is slowing for #AI #Chips #Server #DataCenter. If anything this is just the beginning of a long lasting new era for AI/ML based hardware, software & applications imo.
#SupDup


Summary: Bullish ALLR: $20M cash vs <$2M mkt cap implies massive undervaluation; drug pipeline unpriced; liquidation value alone ~$10/share.

$ALLR ~$1.30 - It had jumped to $2.25+ quickly once I showed but since there has been selling/shorting which has slowly brought stock down. With $20 mln cash on hand and the current mkt cap of <$2 mln makes no sense because the advance drug discovery of its Ovarian Cancer gets ZERO valuation. Even if the company dissolves today, they would still be able to distribute $10/share to stockholders. Stock price drop is puzzling for now but time will tell us if this is dump and scare tactic and then load up cheaply or something else going on imo
#SupDup


Summary: Strong buyer of CING at ~$5.70 on impressive late-stage ADHD trial data and $10M valuation.

$SMMT - UP 65+% this morning making it worth $14.5 bln on encouraging data from its Lung Cancer drug. Stock has slowly risen from $1.55 to $21.50 within a year.
$CING $5.70 has demonstrated amazing data in their late stage clinical trials for #ADHD so at current $10 mln value I am a strong buyer for NT & LT imo
#SupDup


Summary: Expects SMCI to jump to $55–$60 within two weeks.

$SMCI - I have a feeling this will jump to $55 - $60 within next 2 weeks. Lets see !
#SupDup


Summary: Long RKLB (new position, rising from $6.15); also bullish LUNR after dip entry near $4.50, now $5.15+.

$RKLB ~$6.50 now slowly rising. Yesterday was great chance to pick up on dips <$6, same with $LUNR at ~$4.50 and now $5.15+ today, imo
#SupDup

https://t.co/5lyl7b4xix

$RKLB ~$6.15 - Starting a new long position for DT/ST/NT
#SupDup


same with $LUNR at ~$4.50 and now $5.15+ today, imo


Summary: Covered short and went long ASTS.

@diegolaresgoiti $ASTS, I covered my short positions and went long. Check my tweets to see.
#SupDup


Summary: Planning to double long positions in ALLR, KPRX, CING on dips; sees 100–1000% upside within 3 years for these undervalued small-cap pharmas.

Here's my game plan, I really doubt these stocks will go down much further but just in case for whatever reasons it happens, here's my plan. IF they hit below prices, I plan to double my long position on 3 of my current favorites low float/small cap extremely undervalued pharma companies for LT investment because within next 3 years I see all 3 of them rising 100% to 1000% imo.
$ALLR <$1.20
$KPRX <$3.25
$CING <$3.50
#SupDup


I still firmly believe there will be just fine by SEC… the stock will be back to $50 - $150 in 3 yrs. Risk takers on dips with patience will make a lot of money in LT

Summary: Bullish SMCI: SEC/accounting fears overblown, stock at ~$26 is overreaction, sees return to $50–$150 in 3 years on strong tech/demand fundamentals.

$SMCI ~$26 rn = OVERREACTION based on everything we know. Tech is solid, Demand is strong and I assume Accounting manipulation can't be more than 5% of total sales & profits if even that high. So far company has lost $25 bln in valuation which makes me think this is way overblown. Super Micro has close ties to leading giants like $NVDA $AMD $INTC and many others. This is a hot #AI sector server leader whose products directly or indirectly are used by many world's largest companies like $TSLA #X $META $AMZN $AAPL $GOOG, etc.
Anything is possible but I still firmly believe there will be just fine by SEC like many others have paid like $JPM $GS #Tesla $BAC $WFC and hundreds or thousands of small and large cos have paid without admitting any wrong doings. Remember Tyco International scandal? They later got acquired by Johnson Controls $JCI for ~$15 bln.
Once all of this is behind, people will forget and the stock will be back to $50 - $150 in 3 yrs.
Risk takers on dips with patience will make a lot of money in LT. No pain, NO GAIN imo
#SupDup


Summary: RDDT feels overvalued at $20B on fundamentals; AMC comparison implies eventual sharp decline.

industry='Internet Content & Information'

$RDDT $116 - Holly Cow  🚀 Solid run from $35 to $116+ within a year.  At $20 bln valuation to me it feels it is overvalued based on its fundamentals but in this crazy times any thing is possible. Reminds me of the times when $AMC went up to over $70 few years ago and then it tanked to 40 cents needing reverse split lol imo
#SupDup

https://t.co/mYHrdEcXQp


Summary: Adding VCIG at $0.19 for short, near, and long term; bullish catalyst from $10M buyback plan and stock down from $9+.

$VCIG $0.19 - Keep your eyes on it this year. I am adding more for ST, NT & LT like I did with $LUNR at $3.30 and $LUNRW at $0.70 couple of months ago.
Stock used to be $9+ less than 1 yr ago. If mgmt acts on its $10 mln stock repurchase plan it may act like a catalyst. Read the latest ER imo
#SupDup #PennyStock

https://t.co/7vAIbjBXaD


Summary: Long GNLX as a potential multi-bagger long-term, backed by unusual volume and strong after-hours buying.

$GNLX $2.20 rn - Highest volume today in about last 45 days with strong buying in AHrs that pushed the stock to $2.68 at one point. I don't care for little up or down because this one has the potential to be a multi bagger in LT imo
#SupDup


Summary: Bullish SMCI, expects +100% in 2 years citing strong hiring/job postings as indicator of company health.

@MomAngtrades LOL. It will be UP 100% within next 2 yrs.
Just check company's job openings and you will get tired looking through all the new hiring postings which gives you good idea of the health and future imo.


Summary: Short LUNR for day/short-term trade citing massive recent CEO share dumping.

$LUNR $5.50+ Going to Short Sell for DT/ST after seeing massive recent dumping by its CEO.
#SupDup


Summary: Looking to buy ASTS dips under $26 for a short-term $2–$4 spike next week.

$ASTS <$26 - Getting tempted to buy some on dips for ST to sell at $2 to $4 spike next week imo
#SupDup

---

$ASTS $28+ bit ago, happened exactly as I had thought  👇
#SupDup #FastMoney

https://t.co/EIdm9bOYU6


Summary: PLTR fully priced or overvalued after guidance raise; bearish valuation verdict.

@AdamLew11605529 They beat by a bit and raised guidance which is why the stock has jumped up $5 but the valuation now is fully priced if not over valued imo

@SuperDuperInvst
$PLTR....? I dont get it! Up like 5 points today.  Valuation doesnt seem to apply to this stock.


Summary: Buying TSLA under $239 and FSLR around $215 on dips for day/short-term trades.

$TSLA <$239 and $FSLR ~$215 buying on dips for DT/ST
#SupDup


Summary: Covered short and initiated long position in LUNR at ~$5.70.

$LUNR - Covered short from $6.25+, going long now ~$5.70
#SupDup


Summary: Disclosed long position in SMCI with a bullish stance.

@KarenSmithFL @chelsRK I am long and bullish on $SMCI

@chelsRK Agreeeeeee
Lets make some silly putty money this week.


Summary: Long KPRX at $3.60; fundamental case for $10+ based on $30M cash, $300M+ drug deal, and low 1.36M float as catalyst.

$KPRX $3.60 - It went up few days ago to $7.25+ in pre market once briefly but I did not sell. Based on $30 mln cash on hand, the stock should be $10+, add the $300+ mln deal in place for 1 of its drugs in development and the other one which may get even better deal down the road.
Low float of 1.36 mln shares so one exciting news or any hedge fund or mutual fund jumps in this stock could take off like 🚀 🚀 🚀  imo
#SupDup


Summary: Looking to buy SMCI dips below $45 for day/short/near-term trades.

$SMCI $47+ rn
#SupDup #FastMoney

https://t.co/B5YGRgmpOC

$SMCI - Getting ready to load up on dips if it goes <$45 for DT/ST/NT
#SupDup


Summary: SMCI headed to $650-$700 this week, contingent on NVDA beat-and-raise guidance.

@StockXcapital $SMCI - Headed for between $650 - $700 this week but it will all depend on the beat and raise of guidance from $NVDA imo

📊 $SMCI Analysis 🚀🔻

- **Estimated Weekly Low**: 555
- **Estimated Weekly High**: 670

## 🔵 Bullish Levels:
  - **LVL 1 Bullish**: 643 🌟
  - **LVL 2 Bullish**: 663 🌟
  - **LVL 3 Bullish**: 687 🎯
  - **LVL 4 Bullish**: 723 🚀
  - **Bullish Break Out**: > 686-723 📈

## 🔴 https://t.co/cdEYr1V3Sl


Summary: Expects a short-squeeze to drive SMCI from ~$44.75 to $75+, despite weak fundamentals.

$SMCI $44.75 - Not their #AI related servers or products demand nor their sales rise or profits will make the stock go up with what's going on lately but I believe short sellers will eventually make this stock rise to $75+ imo
#SupDup


Summary: WestPark Capital reiterates Buy on NVDA, raises PT to $165 from $127.50.

$NVDA - Nvidia maintained at Buy, Price Target Raised to $165.00/Share From $127.50 by WestPark Capital
#SupDup


Summary: Trump victory catalyst; bullish on crypto and crypto-linked equities today.

With #Trump victory, Not just stock market but #Cryptos will also be on  🔥  🚀 today  imo
#SupDup #BTC #Bitcoin $MSTR $COIN $MARA $RIOT


industry='Financial Data & Stock Exchanges'


Think guys, In 2021 they did a licensing deal for China region rights. Now imagine how big of a licensing deal would be when they do it for USA, Japan, Europe ....It will be huge imo

Summary: Bullish GNLX at $2.15: expects massive licensing deals for USA/Japan/Europe rights to dwarf 2021 China deal worth $171.5M+ in milestones.

$GNLX $2.15 - Think guys, In 2021 they did a licensing deal for China region rights (Click link below). Now imagine how big of a licensing deal would be when they do it for USA, Japan, Europe ....It will be huge imo
Genelux is eligible to receive up to $171.5 million in up-front and development, regulatory, and commercial milestone payments for each of the products developed by Newsoara, plus up to double-digit royalties on net sales.
Genelux grants Newsoara exclusive license to Olvi-Vec and to its oncolytic virus library in the Greater China Region
#SupDup

https://t.co/IuAgINy1PX


Summary: Long SMCI over 1-3 years: worst-case fraud fears priced in after 70% drop, rapid sales/profit growth, AI server demand strong for 2+ years.

$SMCI $383 rn - Even if they inflated some sales perhaps lets assume up to to 7% (which has to be very difficult given their annual sales is $15 bln), stock has dropped from $1225+ to $375 within last 8 months losing $50 bln in company value so worst of the worst is already built into the low current market cap.
Company is growing its sales & profits very rapidly. Operates in the red hot #AI server and infrastructure sector with marquee customers like $NVDA $AMD $INTC etc. Good thing is company's products are in great demand and should be the case for at least next 2 years. In ST stock may see selloff but in next 1 to 3 years this company's valuation should be much higher than current ~$22 bln imo
#SupDup


Summary: Shares Wells Fargo downgrade of Boeing to Underweight with PT slashed to $119 from $185.

$BA - Boeing cut to Underweight from Equalweight, Price Target Cut to $119.00/Share From $185.00 by Wells Fargo
#SupDup


Summary: Bullish CING: market cap <$15M vs $10M+ cash, late-stage ADHD/anxiety pipeline, potential 100% spike.

$CING $4.50 - Current market value is <$15 mln, whereas Cash on Hand is $10+ mln. HUGE potential with its late stage pipeline of #ADHD & #Anxiety drugs under developement and more with PTR platform.
One fine morning we could see it suddenly spike 100%, Great buy for NT & LT investors with vision & some patience imo
#SupDup


Summary: SMCI and AI hardware names NVDA/INTC/AMD seen as beneficiaries of new business partners expanding the ecosystem.

@DanielM_W Good question, I thought about it too but it is the #AI Chip design & manufacturing which $SMCI doesn't do. If anything companies like Super Micro should benefit more from addition of new business partners alongwith $NVDA $INTC $AMD imo

@SuperDuperInvst How does this affect SMCI?


companies like Super Micro should benefit more from addition of new business partners alongwith $NVDA $INTC $AMD imo


Summary: Likes MRNA at $53 for long-term hold.

@cric_bz That was a high flier, I like it here at current price of $53 for LT.
That is why I suggest to always have a stop loss order and to not ever fall in love with any company no matter what imo

@SuperDuperInvst MRNA got me like no other. Lost 60% of my value it when it dropped from $113 (thats when I bought) to current price. I sold all my positions last week.


Summary: Long GNLX at $2.15; expects 100–500% gain in 3 years on FDA approval potential, licensing deals, or buyout.

$GNLX $2.15 - I expect it to rise between 100% - 500% within next 3 years. I am 90% sure it will happen. Multi Billion $ sales potential if one or more of their drug gets FDA approval down the road. Attractive licensing deal prospects or buyout candidate given its promising drug pipeline with huge potential imo
#SupDup


Summary: Long DRUG at $25, expects 75% gain within 1 day, quoting own prior sell call at $47.

$DRUG $25 now, chance to make 75% within 1 day from  👇  🤑
#SupDup

https://t.co/UpbhtMj4tw

$DRUG $47 rn = SELL SELL SELL or Short if you can.
May be it will rise somewhat for a day or so but in few weeks it will drop heavily imo
#SupDup


Summary: Bullish VCIG at $0.135; expects 100% gains within a year.

$VCIG $0.135 - Great chance to buy at low attractive price for penny stock lovers. Easy 100% gains within 1 year imo
#SupDup


Summary: Bullish FSLR; thinks the $17 drop on a minor PT cut from $271 to $266 is unwarranted.

$FSLR $208
Jefferies Adjusts First Solar Price Target to $266 From $271 and the stock drops $17 ? BS imo
#SupDup


Summary: Short ASTS at $29+ for day/swing trade after rapid run from $22.50 the prior day.

$ASTS $29+ feels like a good short for DT/ST given stock was $22.50 just a day ago imo
#SupDup


GRI Bio, Inc. is still VERY UNDERVALUED given its market cap is <$3 mln, Cash on Hand ~$6 mln. Attractive buyout candidate ! Promising drug development pipeline

Summary: Long GRI Bio: trades below cash ($3M cap vs $6M cash), buyout candidate, 500+ compound pipeline, IPF space sees rich acquisition premiums.

$GRI ~$1.05 - GRI Bio, Inc. is still VERY UNDERVALUED given its market cap is <$3 mln, Cash on Hand ~$6 mln. Stock used to be way higher. Low equity float now due to recent reverse split.
Attractive buyout candidate !
Promising drug development pipeline which can get get bigger given they also have library of 500+ proprietary compounds. Recent acquisitions in IPF (Idiopathic Pulmonary Fibrosis) have happened at much higher valuations as seen from  👇 imo
#SupDup


Summary: Initiating short on PLTR; stock dangerously overvalued relative to fundamentals and near-term growth prospects.

$PLTR $42.60+ Starting a Short position. Stock is DANGEROUSLY overvalued based on its fundamentals and NT growth prospects imo.
#SupDup


Summary: Shares HC Wainwright's maintained $32 PT on GNLX; implied bullish endorsement.

$GNLX $2.20 - Genelux Price Target Maintained With a $32.00/Share by HC Wainwright & Co.  😍
#SupDup


Summary: PLTR at $62+ is a bubble on current fundamentals; bearish valuation verdict despite possible further rise.

@KobeissiLetter $PLTR $62+ = Bubble based on current fundamentals but it may rise further reminding me of the dot com era  imo

Palantir, $PLTR, is now trading at 56x Price-to-SALES and 330x Price-to-Earnings.

Do valuation metrics even matter anymore? https://t.co/A1x3aCu6D4


Summary: Author sees SMCI as beneficiary supplying liquid-cooled cluster servers for Tesla's Cortex AI supercluster.

$SMCI liquid cooled cluster servers for $TSLA #AI imo
#SupDup

Video of the inside of Cortex today, the giant new AI training supercluster being built at Tesla HQ in Austin to solve real-world AI https://t.co/DwJVUWUrb5


Summary: Still holds a large position in VVOS.

@JXGCrypto Yes I still own a lot of $VVOS

@SuperDuperInvst Hey super you still in $VVOS? Chart looks coiled for another mental run


Summary: Avoid both AMC and GME on weak fundamentals; GME further hit by post-ER dilution and no clear path to profit growth.

@SPXTOPCALLER @The3Antons $AMC & $GME - I would avoid both based on their fundamentals both both are very speculative stocks as seen from past moves. Unless there is current, then I would just do quick in and out imo

---

@SPXTOPCALLER @The3Antons $GME $21.15 rn - Dpwn 10% post ER today. Management keeps raising funds and diluting. God knows when they will figure out how to use their capital to turn it into generating more sales and profits imo
#SupDup


I would avoid both based on their fundamentals both both are very speculative stocks


$ALLR $1.40 (<$2 mln value, ~$20 mln cash), Anti Ovarian #Cancer drug in phase 2... rising to between 100% to 1000% in future imo

Summary: Bullish on ALLR, KPRX, and CING as undiscovered biotech gems with advanced pipelines likely to attract big-pharma deals or FDA approvals, targeting 100%-1000% upside.

Aktis Oncology got $1.2 bln strategic deal from Eli Lilly $LLY for their phase 1 drug   😍 (Click link below for details).

Mariana Oncology with just pre clinical drug in pipeline got acquired by #Novartis $NVS for a total deal value of $1.75 bln   😍

Compare these deals with my recently shown biotech/pharma gems that have much advanced stage drug development that are yet to be discovered by big players. All 3 stated below have very promising pipelines with strong likelihood of achieving FDA approvals someday making all 3 of these stocks rising to between 100% to 1000% in future imo

$ALLR $1.40 (<$2 mln value, ~$20 mln cash), Anti Ovarian #Cancer drug in phase 2
$KPRX $3.60 (~$10 mln value, ~$30 mln cash), Vision loss related 2 drugs in phase 2 with $370+ mln strategic deal in place for 1 of its drug.
$CING $3.8 (~$11 mln value, ~$10 mln cash), ADHD drugs in phase 3).
#SupDup #RT

https://t.co/HfSUfecWKf


$KPRX $3.60 (~$10 mln value, ~$30 mln cash), Vision loss related 2 drugs in phase 2 with $370+ mln strategic deal in place... rising to between 100% to 1000% in future imo


$CING $3.8 (~$11 mln value, ~$10 mln cash), ADHD drugs in phase 3... rising to between 100% to 1000% in future imo


Summary: Bullish ALLR from $1.45 to $10+ long-term; hopes for institutional buying catalyst.

$ALLR $1.45 - Would be nice to see a Hedge Fund come in and make 1 mln share purchase.
With many ups & downs down the road this could be $10+ stock imo
#SupDup


Summary: Bullish SMCI; expects much higher prices driven by NVDA demand outlook.

$SMCI ~$475 rn rallying, Short squeeze and/or large whales building new long position on dips. It will be much higher in future based on $NVDA outlook imo
#SupDup


Summary: Long KPRX, CING, ALLR for 100%–1000% returns over the next 3 years.

Investors with patience should make a lot of money in LT with:
$KPRX $3.60
$CING <$4.10
$ALLR <$1.40
All with many ups & downs should see 100% to 1000% returns within next 3 years imo
#SupDup


Summary: Still holding CING despite 20%+ loss; expects 100–300% gains near/long term.

$CING $4.20 - 😴 🥲 down 20+% since purchases WTH but it will have its day, I am not happy with the drop but it is for NT & LT and I know I will make 100% to 300% gains on it someday imo
#SupDup


Summary: MSFT is the biggest beneficiary of OpenAI's rising valuation approaching $100B.

#ChatGPT creator #OpenAI nearing $100 billion valuation. Guess who is biggest beneficiary of its rising value? $MSFT #Microsoft imo
#SupDup


Summary: VCIG is undervalued at current sub-$0.15 price; implied hold/accumulate rather than selling into strength.

@loustadtl It is undervalued at current <$0.15 price imo

@SuperDuperInvst Are you buying and selling on these VCIG swings? Tempted to lock some profits now and wait for a dip


Summary: Adding LUNR under $5 for more upside after locking gains; also bullish LUNRW and GNLX near-term and long-term.

$LUNR & $LUNRW - I showed at $3.30 and <$0.70, few times they went to $6+ & $1.75+
I locked my gains on the strong spike and will now be adding under $5 to again make more $ from it.
Don't forget $GNLX $2.15 join me if you like it for NT & LT imo
#SupDup


Don't forget $GNLX $2.15 join me if you like it for NT & LT imo


Summary: Bullish SMCI: dismisses Hindenburg short thesis, cites rising sales and $30B 2025 revenue estimates from analysts.

Hindenburg's Nathan Anderson is full of fluff because stating Super Micro products are inferior makes zero sense.  Strongly rising YoY sales & 2025 revenue estimate for the company from several analysts is to reach $30 bln.
Some of world's largest and best tech & non tech companies are their clients in hot #AI #Server markets.
1 to give an example is just ask tech genius @elonmusk who uses large amounts of $SMCI products at $TSLA imo
#SupDup


Summary: Elliott builds $5B+ stake in Honeywell and pushes for a breakup; relayed activist catalyst implies upside.

$HON - Elliott mgmt builds $5+ bln stake and wants mgmt to split up the company.
#SupDup #Honeywell


Summary: Bullish GNPX: whale accumulation of float could trigger a squeeze-style move higher.

$GNPX $1.75+ rn, Again rising in AHrs. Volume of 280 Mln shares today  😍
Seems like a big whale is gobbling up a lot of available float. If they hold tight you know what can happen  🤑
#SupDup #FastMoney


Summary: Long SMCI at $583, bought on dips for day/short/near-term trades.

$SMCI $583 - Bought on dips for DT/ST/NT
#SupDup


Summary: PLTR is dangerously overvalued at PE 250; fair value $18–$24 vs ~$42, implying ~50–55% downside.

$PLTR $42.40 rn but Fair stock price even being so liberal should be between $18 - $24 based on its fundamentals and EP. Current PE of 250 makes this DANGEROUSLY OVERVALUED.
No one wanted this stock for so long at under $10 and suddenly just because it got added to S&P 500 it is up and now commend $100 bln co valuation imo.
#SupDup


Summary: Long GNLX; patient long-term hold with $10+ upside target from current ~$2.45.

@GOPfail $GNLX $2.45 - Is for investors with patience. In LT this could be $10+ stock imo
#SupDup

@SuperDuperInvst When do dump this one though?


Summary: Holds CING warrants; sees meaningful value if stock rises to $15+.

@PodgornyPrzemek I own some but I guess they will be worth meaningful if & when stock rises to $15+ imo

@SuperDuperInvst Thoughts on $CING warrants? Seems like they’re trading at 5 cents a share and you share in the entire upside: Each warrant is exercisable at any time for the purchase of one share of our common stock at an exercise price of $6.00 per share. Warrants expire on December 10, 2026.


Summary: Restarting purchases of VVOS at ~$2.50 for short, near, and long-term holding.

$VVOS ~$2.50 - Restarting buying for ST, NT & LT
#SupDup


Summary: Still long VCIG and plans to add; bullish on CEO raising stake to 27%.

@WizardCrowsNest Yes, still holding and plan to add more after seeing CEO boosting his stake to $27% imo

@SuperDuperInvst What’s your thoughts on VCIG. Still holding?


Summary: Long GNLX at ~$2.15 under accumulation; targets 100–500% gain over 3 years.

$GNLX ~$2.15 - Under slow and steady accumulation for NT & LT as I see this stock rising to between 100% to 500% within the next 3 years imo.
#SupDup


Summary: Avoid Peloton; decisive bearish stance despite limited recent coverage.

@markidontnoe I would avoid but I haven't been following it lately so I may not be the right person to comment on it imo


Summary: Bullish GRI; multiple near-term catalysts could drive stock to 2x-3x or more from current $0.45-$0.48 range.

$GRI $0.45 - $0.48 = Several NT catalysts, stock could double, triple or more imo
#SupDup


Summary: Building a large long position in CING; US licensing deal for ADHD drug could be worth $500M–$1.5B vs $10M market cap.

$CING ~$5.75 - Adding more slowly and steadily building a large long position for NT & LT
US licensing deal for its ADHD drug could be monster in terms of $ value ($500 mln - $1.5 bln) compared to current $10 mln co valuation.
Remember mgmt states $20 bln global sales potential for their drug(s) imo.
#SupDup


NEW long stock pick $HOUR $1.40. My NT PT is $5+ and LT PT is $10+ imo

Summary: New long on HOUR at $1.40; near-term PT $5+, long-term PT $10+ on 2024 revenue/profit growth and strong holiday season.

NEW long stock pick  $HOUR $1.40
Current market cap $48 mln only.
2023 Sales were $132.1 mln with Net Loss of $2.4 mln
2024 Sales expected to be $165 mln to $250 mln with Net Income of between $4 mln to $6 mln
Sells goods on Amazon mostly but also on Walmart, Etsy and co website. Holiday season sales & profits should be VERY STRONG.
My NT PT is $5+ and LT PT is $10+ imo
#SupDup


Based on fundamentals its a Strong Sell… Current ~$10 bln valuation is by any means overvalued imo

Summary: Short DJT: fundamentally overvalued at ~$10B market cap, no path to profitability or positive EPS in 2+ years.

$DJT $47+ I feel it is a very speculative stock. Based on fundamentals its a Strong Sell (Yes guys I know its a Trump play). Even if Trump gets elected as the President of USA, I can't imagine the company will become profitable in the next 2 years or even report EPS of 1. Current ~$10 bln valuation is by any means overvalued imo.
#SupDup


Summary: Bullish GNLX: $70M market cap looks cheap vs $40M cash, oncology pipeline across multiple indications.

$GNLX $2.10 - Genelux Corp. Drug developement Pipeline consists of Ovarian Cancer, Small & Non Small Cell Lung Cancer, Pancreatic Cancer and also have Animal therapeutics for Hematology & Solid Cancer. This company's current value of $70 mln makes it look very cheap given it has $40 mln cash on hand. Great buy for investors with NT & LT investment goals imo
#SupDup


Summary: Bullish CING long-term on potential licensing royalties from its Precision Timed Release Platform Technology worth hundreds of millions to billions.

$CING $5.90 - Apart from its advanced stage ADHD & Anxiety drugs pipeline, I believe if they start out licensing their Precision Timed Release Platform Technology it could bring hundreds of millions of $ or perhaps billions of $ in royalties in LT imo. Read below and watch the video link at bottom of this post.
#SupDup
A platform technology incorporates multiple systematic and validated processes that can be applied to the development of many drug candidates. This methodology ensures consistency and diminishes the need to reinvent a basic technology for each new product candidate, with the goal of saving time and money. Platform technology incorporates consistent equipment, analytical techniques, and operations. Analytical methods are validated and transferable allowing for transparent decision-making for each product candidate. Platform technologies support efficiency, consistency, and risk minimization.

Cingulate has developed a pharmaceutical platform designated Precision Timed Release Platform TechnologyTM (PTRTM) in which multiple releases of an active pharmaceutical ingredient (API) can be incorporated into one tablet. The API can be delivered precisely throughout the day, with either an immediate or sustained dose. The aim is to create novel extended-release drug products to serve patient needs for consistent and convenient drug delivery. Theoretically more than one API can be incorporated into a tablet, again looking to serve patient needs.

https://t.co/6mjDGZayBr


Summary: Bullish ATLX below $8.30 for both near-term and long-term.

industry='Other Industrial Metals & Mining'

$ATLX <$8.30 - Now its the time to start buying for NT & LT imo
#SupDup #Lithium #Mining #EV


Summary: Retailers and etailers BYON, AMZN, TGT, WMT, COST are real beneficiaries of rate cuts.

$BYON $10.90 - Bed, Bath & Beyond - Overstock owner Beyond, Amazon, Target, Walmart, Costco kind of retailers and etailers will be real beneficiaries of rate cuts imo
#SupDup


Summary: Doubling long position in VCIG below $0.20, buying dips for short/near term with prior premarket high of ~$0.30 as reference.

$VCIG <$0.20 - Doubling my long position. Earlier in pre market stock went to ~$0.30 so buying on dips for ST/NT
#SupDup


Summary: Buying GRI at ~$0.77 for a second rally and long-term hold, avoiding repeat of missing WGS's monster run.

$GRI ~$0.77 - Buying for round 2 rally and to keep some for NT & LT investment because I don't want to make the same mistake by selling too early and missed out on monster run in $WGS imo
#SupDup


Summary: Recommends locking gains or short selling SRRK on spike above $30.30.

$SRRK $30.30+ = Time to lock gains or even short sell on spike imo
#SupDup


Summary: Considering short-selling LUNR short-term after a 300% spike.

$LUNR $9.35 - Getting tempted to start Short Selling for ST on this 300% recent quick spike imo
#SupDup


Sell, Lock your gains into rise to TEENS. Fundamentals are very weak imo.

Summary: Sell BTCT; weak fundamentals, only float/crypto association driving it, avoid chasing peak prices.

$BTCT - Sell, Lock your gains into rise to TEENS. Only good thing about this company is tiny float and association with Cryptos but be careful chasing it and getting sucked into buying at peak prices. Fundamentals are very weak imo. Your money your choice.
#SupDup


don't be getting sucked into buying on hopes & hype and be holding a bag... Their business is all talk, its a pure Trump play but if you look at their sales, its not even $5 mln/yr but market cap is now ~$100 mln. Just be very careful imo

Summary: Warns PHUN is overvalued hype with sub-$5M revenue vs ~$100M market cap after 1:50 reverse split; avoid holding, risk of being left with a bag.

$PHUN $10.65 rn - Be very careful guys. I have traded it many times so I am very familiar with this stock. It is stock to buy when craziness is going on but key will be to get out safely. Unless you are doing quick in & out, don't be getting sucked into buying on hopes & hype and be holding a bag. I have seen it happen many times. They did a 1:50 reverse split earlier this year. Their business is all talk, its a pure Trump play but if you look at their sales, its not even $5 mln/yr but market cap is now ~$100 mln.  Just be very careful imo. Click below link to see.
#SupDup

https://t.co/AAzG2yLl5P


Summary: Will double long position in MBIO at $0.28 or below.

$MBIO $0.28 or under - I will be doubling my long position.
#SupDup


Summary: Bought ASTS at $31.35 for a day-trade/short-term play.

$ASTS - Bought at $31.35 for DT/ST
#SupDup


Summary: Continuing to add CING on dips; near-term PT $15–$20, long-term PT $35+.

$CING ~$5.65 - I continue adding more & more on dips for NT & LT.
My NT PT is $15 - $20 and LT PT is $35+ imo.
#SupDup


Summary: Covered short and is now long ASTS as of this morning.

@spacanpanman @TQInvestor @azurus11 @hypergrowth102 @GaryTeplis $ASTS - I covered all my short position this morning for profits and am long rn fyi
#SupDup

@TQInvestor @azurus11 @hypergrowth102 @GaryTeplis @SuperDuperInvst https://t.co/nPwfzqt24J


Summary: Bullish CING: $11M market cap vs $20B ADHD drug opportunity implies significant upside.

$CING ~$6.50 - Current market cap is just $11 million but the market opportunity for its pipeline ADHD drug is estimated to be $20 billion per company management imo
#SupDup


Summary: Adding CING and VVOS on dips; high conviction both will rise 100%+ within 1 year.

$CING $4.30+ & $VVOS $2.30+ turning green from red  👋
I am adding both on dips because I am very confident that both will for sure rise 100+% within 1 year imo
#SupDup


Summary: Advises taking profits on LUNR, LUNRW, RKLB; expects lower prices ahead offering a re-entry opportunity.

Guys consider locking some of your huge 400% to 600% quick gains in $LUNR $12.35+ $LUNRW $4.50+ and $RKLB $22.50+ imo because you will get an opportunity to buy them all at lower prices.
 But its your decision, I am just saying since I showed you all these when they were sort of unknown names to many of you a few months ago imo.
#SupDup


consider locking some of your huge 400% to 600% quick gains in $RKLB $22.50+


Summary: Shares Roth MKM Buy initiation on GNLX with $10 PT vs $2.20 current price.

$GNLX $2.20 - Just out !
Genelux initiated at Buy, Price Target Announced at $10.00/Share by Roth MKM
#SupDup


Summary: Expects CING to recover and move up soon.

@FC19773 It will have its time, 1 day soon imo


Summary: Buying MBIO under $0.35 for day/short/near-term trade with plans to add on dips; risky but seen as quick reward.

$MBIO <$0.35 - Buying for DT/ST/NT with a plan to add more on dips.
Risky but reward could be quick & good imo
#SupDup


Summary: Author predicts CING is next to spike, implying upside from current level.

$GNLX $2.90 rn, UP ~25% so far just today  🤑
Next to spike could be $CING ~$6 imo
#SupDup

https://t.co/uGYthetba5

$GNLX $2.20 - Slowly and steadily building a large long position in this late stage immuno-oncology drug discovery company Genelux Corp that is working on VERY HARD TO TREAT #CANCER treatments. Cash on hand is sufficient to fund till early 2026. I expect to reap 100+% or more


Summary: Bullish ALLR; expects a licensing deal similar to Merck KGaA/Hengrui to drive massive upside given tiny float and $2M market cap.

$ALLR $1.40 - Would love to see a licensing deal like this happen, IF that happens imagine the stock price on the day of news, it can be $100+ if they can secure similar kind of deal given their current $2 mln market value, tiny float of 1.5 mln shares and  ~$20 mln cash on hand  😍
Someday I hope they can have a similar kind of strategic deal for their lead drug.  Patience will pay off big here imo.

A recent notable example occurred with Merck KGaA’s agreement with Jiangsu Hengrui Pharmaceuticals, involving an upfront payment of approx. $176 million for a PARP inhibitor (HRS-1167) and an antibody-drug conjugate, potentially altogether totaling around $1.5 billion.
#SupDup


Yes I am holding too for now after seeing the demand for its products so strong. It can easily jump $100+ on any good news just like its drop. Many stocks that these short sellers attack go back to where or higher over the time so this may need some patience but I still think it will do very well in LT imo

Summary: Still holding SMCI long-term; strong product demand, expects $100+ jump on good news, confident it recovers from short-seller attacks.

@SuperDuperInvst @TrendSpider I’m still holding smci.  Are you?  What’s the thought process on if we have to bail?


Summary: Buying more ALLR on dips; ongoing accumulation.

@SuperDuperInvst Do you mean we should keep our money in ALLR?


Summary: Buying opportunity in FSLR below $208 for near- and long-term investors.

$FSLR <$208 = Great buying opportunity on dips for NT & LT investors imo
#SupDup


Summary: Building large long position in VCIG; undervalued at $16M market cap vs $30M expected revenues, profitable, with growth potential to $50-150M revenue.

$VCIG $0.20 - Why I like it and am building a large long position slowly & steadily.
At current ~$16 mln company valuation this stock is undervalued & makes it very attractive NT & LT investment given its annual revenues should be $30 mln this year. Don't forget this company is PROFITABLE and have been operating in diverse lucrative sectors. Investments in some good start ups like Chinese Talking Data which may bring windfall income on its IPO. Mgmt is aggressive so in next few years we may see revenues rising to between $50 - $150 mln imo

For six months ended June'24

Revenue: $13.7 mln (up 40% from 1H 2023)

Gross profit: $12.9 mln for the six months ended June 30, 2024 (YoY growth of 57%)

Net income: $5.92 mln (up 27% from 1H 2023)

Share repurchase program for up to US$10 million in 24 months

Company plans to enhance the collection of outstanding receivables totaling $30.1 million as of June 30, 2024, and reduce general and administrative expenses.


Summary: Building large long in CING expecting 2x–3x returns near- and long-term.

$CING - Building a large long position for NT & LT because I feel it will not only double but triple imo
#SupDup


Summary: Warns LUNR may dilute like VVOS given funding needs; implied bearish/take profits.

This is why I repeatedly keep saying make sure to lock some or all of you large quick gains.
$VVOS $3 - Announced dilution by raising funds at deep discount on yesterday's spike of 300% at one point.
Same can happen with $LUNR $9.35 so keep that in mind since they need more funds to execute their business imo.
#SupDup

https://t.co/9BwbM853Ur


Summary: PLTR is dangerously overvalued at $135B given current fundamentals even with near-term growth prospects.

$PLTR $58.75 = DANGEROUSLY OVERVALUED now at ~$135 bln valuation based on its current fundamentals and even factoring its decent NT growth prospects imo.
#SupDup


Summary: Long CING: imminent USA licensing deal for ADHD drug expected to drive $5–$20 price rise from ~$6.

$CING ~$6 - Keep your eyes on it. USA licensing deal for their ADHD drug should get sealed any day from now through end of this year. As and when that happens and gets announced the stock will see rise of between $5 - $20 imo
#SupDup


This stock should be $0.50+ if not $1+ but certainly not where it is today based on its fundamentals, rising sales & profits, investments and future potential. I have been adding slowly & steadily for ST, NT & LT.

Summary: Long VCIG from $0.20; targets $0.50–$1+ on undervalued equity stake in TalkingData IPO, rising fundamentals, and expected big news within 2 weeks.

$VCIG $0.20 - At current low $17 mln value, Just its equity stake in China's fast growing Talking Data should reap $100+ mln on IPO in NT. Check Talking Data growth with its marquee clients - you will be extremely impressed.

This stock should be $0.50+ if not $1+ but certainly not where it is today based on its fundamentals, rising sales & profits, investments and future potential. It used to be $9.25+ less than 1 year ago when most of the progress has been made in last 9 months.
Check it out, you will love this very company with operations in diverse sectors. At current dirt cheap valuation I have been adding slowly & steadily for ST, NT & LT. I am expecting some big news within next 2 weeks imo.
#SupDup #FinTech #AI #Robotics #Consulting #Crypto #Bitcoin #Mining #DataCenter


Summary: Endorses $12 price target on GRI, currently trading at $0.52; strongly bullish implied by reaction.

@SuperDuperInvst $GRI got a $12 price target last week https://t.co/NNSk3tnbjr


LOAD UP $HOUR 🚀 Don't make me do the same with $HOUR because it will too rise much higher slowly with many ups & downs like all others I mentioned above imo

Summary: Strong buy on HOUR; author expects it to rise much higher, analogizing to past calls on LUNR, AAOI, RKLB.

LOAD UP $HOUR  🚀
I SCREAMED for days and weeks when $LUNR was <$3.30 (Now $12+) and $LUNRW was <$0.70 (Now $4.10+). Same with $AAOI when it was <$8.15 (Now $29) and $RKLB when it was <$6.15 (Now $21).
Don't make me do the same with $HOUR because it will too rise much higher slowly with many ups & downs like all others I mentioned above imo
Buy Low Sell HIGH = HUGE  💰
#SupDup #FastMoney


Summary: Long SMCI from ~$48 to $75–$150 in 2–3 years; allegations unproven, worst-case fine manageable, AI server demand + profitable growth intact.

$SMCI ~$48 rn - There is smoke so I am sure there is fire but all the allegations made by a short seller with agenda have yet to be proven correct. Even if mgmt sold to some Russian or Chinese companies they would be via a middle party so that I am not so worried given those sales figures won't be big. As for accounting issues, I can not imagine mgmt inflated sales by more than 5%. When all of this is over worst case scenario company will be fined $25 mln to $200 mln. Mgmt will fire few ELT folks most likely replace CFO and 2 - 3 years from now this stock will be perhaps between $75 - $150 given #AI related company's cluster rack AI servers, DLC systems and other hardware are in huge demand. Remember company is growing very rapidly due to it being in bed with $NDVA $AMD $INTC and other marquee clients and is highly PROFITABLE imo.
#SupDup

https://t.co/ap5TUKn8NV


Summary: Buying back LUNR under $5.15 after selling higher; bullish re-entry.

$LUNR <$5.15 rn, time for me to buy back now after selling at higher prices imo
#SupDup


Summary: Calls VVOS a screaming buy at $2.25 for near-term and long-term investors.

$VVOS $2.25 = SCREAMING BUY for NT & LT investors imo
#SupDup


Summary: Adding to long CING on dips; bullish on imminent US licensing deal for ADHD drug with multi-billion dollar market opportunity.

$CING - Bought more at $6.35 and plan to add more on dips if I see it go down.
USA licensing deal for their ADHD drug likely possibly within next 3 months which could be massive given the global sales opportunity is estimated to be billions of $  per mgmt imo
#SupDup


Summary: ALLR could skyrocket if a licensing or development partner deal is announced.

@PodgornyPrzemek I am sure you will have plenty of time to load up. It will all depend on many factors but IF they line up a licensing or development partner the stock could skyrocket upon release of such news imo.

@SuperDuperInvst What do you think timeline on $ALLR is. Curious how much time there is to load up 😁


Summary: Endorses buying CING.

@SuperDuperInvst Would have bought when you first mentioned.. will plan to buy CIGR


Summary: Expecting positive catalyst for CING this week.

$CING - I am expecting some good news this week, lets see if it happens or not !  🤞
#SupDup


Summary: Long GRI: trading below cash value at <$3M market cap vs ~$6M cash, plus drug pipeline and 500+ proprietary compounds.

$GRI  $0.70  - Current company valuation is less than $3 mln despite ~$6 mln cash on hand and drugs in development stages. Remember they also have library of 500+ proprietary compounds that can further enrich their drug discovery pipeline.
Recent acquisitions in IPF (Idiopathic Pulmonary Fibrosis) imo  👇
#SupDup


Summary: Long VCIG at $0.20 with ST target $0.40–$0.75.

$LUNR <$5 now, yesterday almost 100 mln shares traded and stock went above $6.
I am glad I locked my gains so I could buy back cheaper and wait for the next rally. Bringing profits into $VCIG $0.20 to someday in ST to sell between $0.40 - $0.75 imo
Buy low sell HIGH = Profits.
#SupDup


Summary: Bullish FSLR at ~$200; any dip below $200 seen as even better buying opportunity across short, near, and long term.

$FSLR ~$200 rn and even much better if it goes <$200, it would be great buying opportunity for ST, NT & LT imo
#SupDup


Summary: Expects TSLA to rise tomorrow following the Robo Taxi event.

$TSLA $241 rn - I have a feeling stock will rise tomorrow after the Robo Taxi event imo
#SupDup


Summary: Bullish VCIG on planned global expansion with 4 new offices (NY, London, Frankfurt, HK).

$VCIG - Per mgmt 4 new offices coming soon which to me means they have plans to expand globally imo
New York
London
Frankfurt
Hong Kong


Summary: Shares Deutsche Bank Buy reiteration on ASTS with PT raised to $63 from $22.

$ASTS $27.10 - AST SpaceMobile maintained at Buy, Price Target Raised to $63.00/Share From $22.00 by Deutsche Bank  😍
#SupDup


Summary: Long GNPX at $0.47 on low float, oncology/diabetes pipeline; targets double, triple or more.

Missed out on quick rise of 400% in $GRI? Don't worry, here's another hot stock trade idea.

$GNPX $0.47 - #Oncology & Diabetes drug discovery pipeline. Promising #Cancer trials ongoing. Very low equity float of ~2.5 mln shares and market value of under $1.5 mln which makes this very attractive buy for NT & LT investors. Easy double, triple or even higher potential imo
#SupDup


Summary: Adding to long CING on dips; buyers lining up at current levels.

$CING $4.20 - Buyers lining up. I am adding on dips after spike to $5 yesterday.
#SupDup


Summary: Disclosed large long position in GNLX under $2.

$GNLX <$2 - Bought a large block
#SupDup


Coiled like spring, keep your eyes on it... extremely dirt cheap at current $11 mln co. valuation imo

Summary: Long CING as extremely cheap vs peer DRUG; $11M market cap seen as deeply undervalued.

$CING $4.50 - Coiled like spring, keep your eyes on it.
Compared to $DRUG $75+ (valuation of $350+ mln), Cingulate is extremely dirt cheap at current $11 mln co. valuation imo
#SupDup


Summary: TSM beat + raised guidance on AI demand should ignite a sector rally; flags NVDA, SMCI, AMD as beneficiaries.

$TSM ~$205 rn - UP $17+ or ~10% in pre market after releasing their Q3 ER. Strong earnings that beat street expectations & raised guidance on huge #AI chips demand.
This bodes well for the industry and should ignite strong rally in the sector. Keep an eye on $NVDA $SMCI $AMD imo.
#SupDup


should ignite strong rally in the sector. Keep an eye on $NVDA $SMCI $AMD imo


Summary: Buy CING at $5.

@VerSatya Look into buying $CING $5 imo. Good luck
#SupDup

@SuperDuperInvst Thank you. You have blessed me and my family with this one. 😭🙏🏼 Now waiting for the next blessing you have in store for us. 😆


Summary: Cautiously bullish SMCI: preliminary Q1 FY2025 numbers below prior guidance but viewed as credible now that books appear clean.

$SMCI - #'s without cooking the books much lower but feels realistic at least  👇  imo

Preliminary First Quarter Fiscal Year 2025 Highlights.
The Company expects to report the following financial information for the quarter ended September 30, 2024:

-- Net sales in a range of $5.9 billion to $6.0 billion compared to its previous guidance range of $6.0 billion to $7.0 billion -- GAAP and non-GAAP gross margin of approximately 13.3% -- GAAP diluted net income per common share in the range of $0.68 to $0.70 compared to its previous guidance range of $0.60 to $0.77 -- Non-GAAP diluted net income per common share of $0.75 to $0.76 compared to its      previous guidance range of $0.67 to $0.83

The non-GAAP gross margin expected to be reported for the first quarter of fiscal year 2025 adds back stock-based compensation expense of $4 million. The non-GAAP diluted net income per common share expected to be reported for the first quarter of fiscal year 2025 includes adjustments for stock-based compensation expenses of $50 million, net of the related tax effects of $17 million.

The Company expects to report total cash and cash equivalents of approximately $2.1 billion and total debt of approximately $2.3 billion with bank debt      comprising approximately $0.6 billion and convertible notes of approximately $1.7 billion.
#SupDup


Summary: Bullish SMCI as a major AI chip cycle beneficiary, contingent on coming out clean.

@Beth_Kindig Yes and $SMCI too will be huge beneficiary IF they come out clean imo

UBS expects AI chip sales to rise nearly 46% YoY next year, from $168 billion in 2024 to $245 billion in 2025.

$NVDA $AMD $INTC $AVGO $MU $QCOM


Summary: Bullish SMCI; expects valuation to be way higher down the road.

@TicTocTick Company will be way higher in valuation down the road just like Adani Enterprises imo.

$SMCI will avenge Adani.

I will explain later why.

Now 540.


Summary: Bullish ALLR on tiny 1.5M float; heavy short interest likely forces a squeeze cover at much higher prices.

$ALLR - Someone is shorting heavily like we saw with $GNPX $ATNF $SMMT $GRI but we all know eventually they had to give up and cover at astronomically higher prices. For example those that shorted $DRUG < $2 had to cover at $50 - $79 few days later due to thin float.
With float of just 1.5 mln shares on this one, Shorts are playing with fire imo.
#SupDup


Summary: Bullish SMCI for investors willing to hold 1–3 years.

@TrendSpider YES for investors with courage and patience to hold for 1 to 3 yrs imo

$SMCI bulls have confidently supported the stock at 20x earnings for over a year...

Is it time for them to start accumulating again? 🤔 https://t.co/OvbmFOeFaM


Summary: Buy CING at ~$6; expects near-term reversal on ADHD drug FDA approval potential and large pharma licensing upside.

$CING ~$6 now, Didn't I warn at $19 a couple of weeks ago. Those that short sold on that day would have seen profit of 200+% quickly  🤑
Now its time to BUY if you have some patience. I see it making a U turn in NT. Their ADHD drug could bring in Billions of $ in future if approved which I feel will get a green light from FDA and should attract a large pharma to license paying huge upfront amount and royalties on future sales imo
#SupDup #FastMoney

https://t.co/WArJMd6sY7


Summary: Truist reiterates Buy on NVDA, raises PT to $148 from $145.

$NVDA $123 - Nvidia maintained at Buy, Price Target Raised to $148.00/Share From $145.00 by Truist Securities
#SupDup


Summary: Long GNLX; expects break above $2.30 to target $2.55–$2.80.

$GNLX - Break $2.30 next stop $2.55 - $2.80 imo
#SupDup


Summary: Loop Capital maintains $175 PT on NVDA; author shares/endorses the bullish call.

$NVDA $126 - Nvidia Price Target Maintained With a $175.00/Share by Loop Capital


Summary: Buying CING at $7.20 for day-trade/short-term.


Summary: Plans to double long CING on dips; sees 10x-100x upside on $25B+ ADHD/Anxiety pipeline and Precision Time Release drug tech.

$CING $5.85 - I plan to double my long position if I see further dips because with what they have on their plate is 10x to 100x more than the current dirt cheap company valuation based on $25+ bln sales potential for their ADHD and Anxiety drugs pipeline and on top their Precision Time Release drug technology that can be monster potential in the super duper large global Pharma industry imo (Click link below).
#SupDup

https://t.co/4WnKrlP3Zy


Summary: Bullish INTC: expects Intel to win Amazon AI chip manufacturing business.

@JimL716 Believe it or not Intel is going to help Amazon manufacture its home designed #AI chips imo


Summary: Shares UBS reiterated Buy on Moderna with PT cut to $108 from $140; adopts bullish stance.

$MRNA $52.80 rn - Moderna maintained at Buy, Price Target Cut to $108.00/Share From $140.00 by UBS  🤔
#SupDup


Summary: Short selling LUNR at $6 for a day/swing trade.

$LUNR $6 - Time for me to short sell 4 DT/ST
#SupDup


Summary: Bullish CING at $5.25, expects large gains in both near-term and long-term.

We are going to make a LOT OF MONEY on $CING $5.25 with some patience in both NT & LT imo
#SupDup


Summary: Short CAVA above $120.

$CAVA >$120 seems like a good short sell imo
#SupDup


Summary: Avoid BIVI after sharp rise; expects dilutive capital raise.

@PinkKittyLatina I would stay away from $BIVI for now with the sharp rise. They are going to raise capital imo
https://t.co/p21eL7dFwP

@SuperDuperInvst U check $BIVI ? Looks good too !! IMO


Summary: Long ALLR, CING, MBIO as dirt-cheap cancer-drug pipelines vs ImmunityBio; author sees goldmine valuations long-term.

$IBRX $7.25+  ImmunityBio a Cancer drug discovery co's stock rises 66+% in  a day just because yesterday Barron's mentioned about the company in an article. Value rises ~$2 bln to ~$5 bln valuation   😍
You will notice all their drugs are in phase 1 or 2 clinical stages.
Compare it with our baby's pipelines and current dirt cheap valuations of $ALLR $2 mln $CING $13 mln $MBIO $11 mln.  We are sitting on goldmines in LT imo
#SupDup


Summary: Short DRUG at $30+; sell into the spike.

$DRUG $30+ = Short / Take PROFITS on spike and run away fast imo
#SupDup


Summary: Conditional near-term spike in NVDA and semis sector on strong NVDA earnings/outlook.

@THEreal_HM_ Yes, but be careful. IF $NVDA earnings and outlook is strong the entire sector should get a spike for time being imo

@SuperDuperInvst How are you feeling about it today? Think it will build back to 160? Then short it again?


Summary: Bullish CING: Phase 3-ready ADHD drug with strong data and M&A potential at sub-$20M market cap; likely buyout target.

$CING - Current market cap <$20 mln. After seeing many recent deals of $1+ bln for pre clinical or stage 1 drugs, I feel Cingulate with advanced Phase 3 trials completion & ready for NDA submission with FDA for its ADHD drug, it could possibly fetch a very strong buyout offer from a larger pharma given data looks extremely promising with billions of $ sales potential upon approval of drug imo.
#SupDup


Summary: ALLR undervalued at <$2; cancer drug pipeline + ~$20M cash support $10+ fair value.

$ALLR - Here we go volume and price getting stronger  🧨  🔥  soon  🚀
Based on the #Cancer drug pipeline & progress,  ~$20 mln cash on hand, stock should be at least $10+ rn and not <$2 imo
#SupDup


Summary: Expects CING and CINGW to repeat 100–400% gains seen in VVOS/LUNR; buy at current depressed prices.

Buy when no one wants it just like $VVOS at $2 or $LUNR at <$3.50 or $LUNRW at <$0.70
With some patience you all saw these stocks jumped 100% to 400% within a few months.

Same thing will happen down the road to $CING $5 and $CINGW $0.06 imo
Buy Low Sell HIGH = PROFITS
#SupDup


Summary: Bought TSLA at $234.25 for day/swing/near-term trade.

$TSLA - Bought at $234.25 for DT/ST/NT
#SupDup


Summary: Expects SMCI to reach $650–$700 next week.

$SMCI - I still feel like next week we will see it between $650 - $700 imo
#SupDup


Summary: Palantir valuation deemed outrageous vs fundamentals; implied bearish.

@AdamLew11605529 Valuation is just outrageous rn based on fundamentals imo.

@SuperDuperInvst From an article i was reading.
Definitely waiting to see what happens with this stock before investing.  Short selling seems like a great play.

The problem with Palantir is its stratospheric share price.

https://t.co/xaLtyD5wp6


Summary: Bullish on HOUR; buyers coming in, tight float expected to drive price higher once volume picks up.

$HOUR - Buyers coming in, price strengthening. Once volume picks up & the penny flippers are gone it will be very exciting due to super duper tight thin float. Hopefully they won't have to halt trading before I can buy more imo.  🚀
#SupDup


Summary: Expects a short squeeze / MM trap driving a volume and price surge in ALLR over the next few weeks.

$ALLR - MM & Shorts are gonna get trapped heavily just watch for volume & price surge in next few weeks imo  👀  🚀
#SupDup


Gimme Gimme Gimme more love adding on dips. why flip for a $1/share profit when you could down the road for $10/share or more in profits imo

Summary: Adding CING on dips; sees $10+ upside vs current ~$5.40, criticizing short-term flippers.

$CING $5.40 - Gimme Gimme Gimme more love adding on dips. Who are these penny flippers? Even if they got stocks for $4.50 to $5 (which I doubt because I think capital raise was done at $5.50 - $8/share range) in the last funding round, why flip for a $1/share profit when you could down the road for $10/share or more in profits imo
#SupDup


Summary: Accumulating CING at $5.30, expects significantly higher prices over time.

$CING $5.30 - Lotto jackpot winning ticket for investors with some patience. I am buying more & more slowly and steadily to sell someday at much much higher prices imo
#SupDup https://t.co/fRyfNKfrDW


Summary: Long SMCI; near-term target $500+, expects much higher in both near and long term.

$SMCI ~$460 rn on its way to $500+, In NT & LT it will be much much higher imo
#SupDup

https://t.co/1ppLDZx72I

$SMCI $385 rn - TOTAL MANIPULATION by big players.
A week ago ALL WAS WELL when stock was $550 and gave Buy rating with $950 PT, today Price Target Cut to $500.00/Share From $950.00 by JP Morgan.
Many others had buy ratings when stock was $600 - $1000 and now many of them have


Summary: Long SMCI; rapid growth + undervaluation vs NVDA's $2.91T market cap implies far higher value from current ~$26.5B.

@MCFC_SOL $SMCI - It is growing very rapidly and based on its current fundamentals comparing it to valuation of $NVDA ($2.91 trillion), I feel Super Micro is very undervalued and will be worth way more than today's ~$26.5 billion value imo
#SupDup

@SuperDuperInvst You think we will see it in $smci? Think theres enough value left in it that it wont be hit too hard


Summary: Actively accumulating SMCI on dips, adding more this week for near-term and long-term positions.

@ripster47 @KanadRaul I am accumulating on dips and will add more this week for NT & some for LT.

@KanadRaul $SMCi still not confirmed, still heavy  need to wait


Summary: Short UPST at ~$70, dropping fast; calls it easy money within a day.

$UPST ~$70 rn, easy money within a day given it is dropping fast  👇  🤑
#SupDup #FastMoney

https://t.co/eJZ5UEvQRw

$UPST $85.50+ = DANGEROUSLY OVERVALUED currently based on ALL THINGS CONSIDERED.
Fair price should be no more than $65 currently imo.
I am going to start short position with a stop loss at $88.50
#SupDup


Summary: Strong sell/short call on DRUG at $57.70+; expects heavy decline from here.

$DRUG $57.70+ rn = SELL SELL SELL, Short Sell it will tank heavily imo
#SupDup


Summary: Long CING to $10+ within 1 year from ~$4.40; strong long-term buy call.

$CING $4.40 - I see stock rising to $10+ within 1 year. Great LT buy imo
#SupDup


Summary: Expects VCIG to rise to $0.10+ today on strong morning volume.

$VCIG - Volume is very strong so far this morning, slow rise heading to $0.10+ this afternoon imo
#SupDup #PennyStock


Summary: Adding to VCIG position below $0.12 to lower cost average; live long.

$VCIG <$0.12 - Adding to cost avg
#SupDup #PennyStock


Summary: Expects NVDA to beat and raise guidance, triggering a strong tech sector rally.

$NVDA - All 👀 on it as it will report qtr results on Wednesday. IF they beat and raise guidance going forward (which I believe will happen) there will be a strong rally in tech sector imo.
#SupDup


there will be a strong rally in tech sector imo


Summary: BA and SMCI undervalued relative to revenues/earnings; PLTR overvalued at $95B+ on minimal sales.

$BA $150 - Valuation tanks to $95 bln now with sales of $74 bln 💤
$PLTR $43 - Valuation rises to $95+ bln on just sales of $2 bln on EPS of 0.17  💤
$SMCI $48 - Valuation tanks to $26 bln now with sales of $15 bln and EPS of 20+  💤 imo
#SupDup


$PLTR $43 - Valuation rises to $95+ bln on just sales of $2 bln on EPS of 0.17 💤


$SMCI $48 - Valuation tanks to $26 bln now with sales of $15 bln and EPS of 20+ 💤 imo


Summary: HIMS trading down below $15.25 on Eli Lilly's cheaper Zepbound vial announcement; bearish read for HIMS.

Drug Manufacturers - Specialty & Generic

$HIMS <$15.25- Down on Eli Lilly announcement - In response to high demand for its weight-loss treatment, Eli Lilly announced that a cheaper form of Zepbound 2.5 mg and 5 mg single-dose vials -- priced at a 50% or more discount compared to other weight-loss drugs will be available for self-pay for patients with an on-label prescription.


Summary: Buying SMCI at $398 or below following an $85+ drop; explicit buy call at that level.

$SMCI $398 or under on today's $85+ sudden drop  = BUY BUY BUY for me.
#SupDup


Summary: Extremely bullish SMCI, NVDA, AMD as the biggest pillars of the AI revolution; biggest stakes on SMCI.

Not pumping but am extremely bullish on the prospects of the company which is at the forefront of #AI.
Bro only IF you know the power of Artificial Intelligence + ML & LMM.
Applications using AI chips/servers will change the way so many things are done currently. You ain't seen nothing yet. $SMCI $NVDA $AMD are the biggest pillars of the new revolution imo

@SuperDuperInvst lol you’ve been pumping this bad boy since like 800 or so hilarious


$SMCI $NVDA $AMD are the biggest pillars of the new revolution imo


Summary: Bullish CING on potential of its Precision Timed Release platform as disruptive tech in the $1.6T pharma industry.

$CING $5.80 - I believe their Precision Time Release drug delivery mechanism could emerge as #Disruptive unique technology in the $1.6 Trillion global Pharmaceuticals industry imo
#SupDup @CathieDWood

A platform technology incorporates multiple systematic and validated processes that can be applied to the development of many drug candidates. This methodology ensures consistency and diminishes the need to reinvent a basic technology for each new product candidate, with the goal of saving time and money. Platform technology incorporates consistent equipment, analytical techniques, and operations. Analytical methods are validated and transferable allowing for transparent decision-making for each product candidate. Platform technologies support efficiency, consistency, and risk minimization.  Cingulate has developed a pharmaceutical platform designated Precision Timed Release Platform TechnologyTM (PTRTM) in which multiple releases of an active pharmaceutical ingredient (API) can be incorporated into one tablet. The API can be delivered precisely throughout the day, with either an immediate or sustained dose. The aim is to create novel extended-release drug products to serve patient needs for consistent and convenient drug delivery. Theoretically more than one API can be incorporated into a tablet, again looking to serve patient needs.  https://t.co/6mjDGZayBr


Summary: Pullback expected in OKLO & DJT; SOUN has long-term potential; MSTR continues Bitcoin-driven rally with high volatility.

$OKLO & $DJT will pull back eventually, $SOUN has potential in LT. $MSTR is pure #Bitcoin play so it could continue its rally but will remain very volatile. $SAVE lets see if they can manage to save their Spirit Airlines from becoming bankrupt. Not familiar with $RGTI imo
#SupDup


$MSTR is pure #Bitcoin play so it could continue its rally


Summary: Bullish HOUR: breaking $2 triggers short covering and new buyer influx.

$HOUR - Break $2 and it will trigger massive short covering and new buyer influx.
At 2 o'clock it will be interesting imo  🔥  🚀
#SupDup


Summary: Holds HUMA long at $5.30, expects imminent FDA approval as catalyst.

$HUMA ~$6.50 rn - I feel FDA approval coming soon, glad I loaded a day ago at $5.30
#SupDup


Summary: Roth MKM reiterates Buy on LUNR, PT raised to $10 from $7; author shares/adopts the call.

$LUNR $5.75 - Intuitive Machines maintained at Buy, Price Target Raised to $10.00/Share From $7.00 by Roth MKM
#SupDup


Summary: Bullish SMCI on dirt-cheap valuation and strong product demand; stock has priced in worst-case scenario.

$SMCI - The day it files its long delayed 10k and IF there are no material changes the stock could spike $5 - $15 easily but the long delay makes me wonder if the mgmt indeed has cooked the books. Irrespective the stock currently factors worst of the worst given its dirt cheap valuation of just $27 bln. Company's fundamentals are still great and demand for their products is extremely strong due to supplies to $NVDA $AMC $INTC $TSLA and many others globally imo
#SupDup


Summary: Accumulating VCIG on dips; bullish on the pullback despite volatile price action.

@JXGCrypto Yes it makes no sense but that's stock market. I am accumulating on dips

@SuperDuperInvst What’s your take on VCIG dipping hard because the CEO has announced he’s increasing his amount of shares in the company? It’s insane to me, it jumped 20/30% pre market and now it’s down 20% on the day. It makes no sense what so ever?? What’s your take?


Summary: Adding to CING and MBIO on valuation catalyst; buying ALLR on insider purchase of 118,500 shares at $2.11.

Adding some more $CING $MBIO after seeing valuation rise of $2 bln today in $IBRX and $ALLR too after seeing an insider buy 118,500 shares at $2.11/share imo.
#SupDup


$ALLR too after seeing an insider buy 118,500 shares at $2.11/share


Summary: Bullish VCIG on large-block accumulation activity.

$VCIG - Large blocks under accumulation  👀
#SupDup #PennyStock


Summary: Bought ASTS at $33.35 on a dip, holding for quick/day/swing trade.

$ASTS - Bought at $33.35 on dips from $39+ earlier for QT/DT/ST
#SupDup


Summary: Long VCIG; expects stock much higher near- and long-term on sales/profit news, may add on dips.

@lance_chapman8 Same here but lets hope with all the news and what's going on with the sales & profits, stock will be much higher in NT & LT. I may add more to cost avg on dips imo

@SuperDuperInvst Taking a beating on this and $VCIG


Summary: Long SMCI long-term; believes valuation will be significantly higher from current $420+ levels.

$SMCI $420+ rn, yesterday's purchases on dip to <$400 making money. Those that dared and loaded at $375 - $410 should be happy  🤑
I still believe in LT this company's valuation will be WAY HIGHER imo
#SupDup


Summary: Still long SMCI, considering averaging down on dips; bullish NVDA on expectation of super-strong results.

I trade fast at times based on any new developments. My plan wasn't to close the long position because I believe Nvidia results will be super strong and that would have moved up SMCI stock. Plan was to sell and re buy cheaper after that report this morning. I still own some which I am in solid red with today's selloff for now but may cost average on dips.

@SuperDuperInvst Ok, but since you were hyping the stock repeatedly and trashed the report that came out from hindenberg, I assumed you were still in it until you said you weren't.   It would have been nice to say you were getting out yesterday and caution your followers.


I believe Nvidia results will be super strong


Keep your eyes on it. USA licensing deal for its ADHD drug news should come out in ST which is a huge catalyst imo

Summary: Bullish CING sub-$7; expects imminent US licensing deal for ADHD drug as a major near-term catalyst.

$CING <$7  - Keep your eyes on it.
USA liicensing deal for its ADHD drug news should come out in ST which is a huge catalyst imo
#SupDup


Summary: Bullish GNLX well above $4 on anticipated favorable clinical trial data for Ovarian and Small Lung Cancer.

@m92di It will rise much higher than that once they announce favorable data read outs of their hard to treat Ovarian Cancer & Small Lung Cancer clinical trials imo

@SuperDuperInvst What do you think about GNLX?
Will it go up to $4 this month?


Summary: Bullish GNLX: trading at $2.20 vs $30+ 1-yr high with no negative developments, only progress per CEO.

$GNLX $2.20 - 1 yr high was $30+, absolutely nothing has changed negatively over the last year. Only thing that has happened during last 12 months is more progress on all fronts as stated by the CEO in recent shareholder meeting imo
#SupDup


Summary: Aggressively buying ALLR below $1.50, expecting a massive short squeeze on thin float + upcoming catalyst.

$ALLR <$1.50 = LOAD LOAD LOAD is what I am doing as I anticipate huge run up on next exciting news that will create massive mother of all short squeezes due to super duper thin float imo.
#SupDup


Summary: TSLA up $50+ within days driven by Trump election win.

$TSLA ~$300 rn  😍
UP $50+ within days due to Trump win
#SupDup


Summary: Bullish GNLX: phase 3 trial in ovarian cancer, $75M market cap with ~$40M cash, called one of the most attractive oncology development stocks.

$KROS ~$55 - UP $10 with $2+ bln market cap now on just the news of clinical trial enrollment completed in the Phase 2 of their TROPOS trial.
$GNLX $2.20 - In advanced phase 3 clinical trials for hard to treat Ovarian #Cancer with several others in different stages of clinical trials for various kinds of cancer but its current market cap is barely $75 mln out of which about $40 mln is cash on hand. This is one of the lowest valued & most attractive oncology drug development co stock with so advancements to their drug discovery imo
#SupDup

https://t.co/3eukvcBJT0


Summary: Bullish CING; targets $15–$35 on potential US licensing deal for lead ADHD drug, conditioned on mgmt avoiding dilutive fundraising.

$CING $5.45 - If the mgmt doesn't rush into raising funds at current dirt cheap valuation, this stock could easily jump to between $15 to $35 upon news of licensing their lead ADHD drug for USA rights imo
#SupDup


Summary: SMCI should spike back above $500 by month-end.

$SMCI - It should spike back to $500+ by the end of this month imo
#SupDup


Summary: Expects ATLX to reach $13–$19 from $7.75 within 6 months, ~70–145% upside.

$ATLX $7.75 - I expect teens ($13 - $19) within next 6 months imo
#SupDup #Lithium


Slowly and steadily building a large long position in this late stage immuno-oncology drug discovery company Genelux Corp ... I expect to reap 100+% or more returns on this one in NT & LT imo

Summary: Building large long in GNLX at $2.20; expects 100%+ returns near-term and long-term on late-stage immuno-oncology pipeline.

$GNLX $2.20 - Slowly and steadily building a large long position in this late stage immuno-oncology drug discovery company Genelux Corp that is working on VERY HARD TO TREAT #CANCER treatments. Cash on hand is sufficient to fund till early 2026. I expect to reap 100+% or more returns on this one in NT & LT imo
#SupDup


Summary: Long SMCI to $60–$75 on monster AI demand and superdupergrowth; manipulation overhang already cleared.

$SMCI $50.50+ rn, what did I say few weeks ago. Big players used scare tactic and grabbed stocks at dirt cheap valuations. It was total manipulation just like HR & other involved parties like $GS affiliates may have done with India's Adani Enterprises a year ago. They grabbed billions of dollars worth of stock at throw away prices and are UP 200% now a year later.
#AI demand is monster and this company is growing at a Super Duper pace. Stock is going to slowly inch up to $60 - $75 with many ups & downs imo
#SupDup

https://t.co/MOQuR3gY4F


Summary: VCIG seen as very undervalued on Malaysia's booming economy and stock market.

$VCIG $0.135 - Very UNDERVALUED given Malaysia's economy is booming and so its stock market. Look at this new IPO that just listed imo
#SupDup

https://t.co/xsrjagBG8H


Summary: Buying DGLY at $0.92 as a short/near-term play in the same hot sector as AXON, which is also flagged bullish.

$DGLY $0.92  ⚡⚡⚡
Good ST/NT buy imo. I am buying right now.
Operates in the same sector as $AXON $456+ that is on  🔥  🚀
Check it out !
#SupDup


Summary: Buying BYON under $9.70 and LUNR around $4.80 for short/near-term trades.

$BYON - Buying <9.70 and $LUNR ~$4.80 for ST/NT
#SupDup


Summary: Considering short selling AMD at $161.25+, targeting quick/day/short-term trades.

Getting tempted to Short Sell $AMD @$161.25+ for QT/DT/ST
#SupDup


$UPST $85.50+ = DANGEROUSLY OVERVALUED currently based on ALL THINGS CONSIDERED. Fair price should be no more than $65 currently imo. I am going to start short position with a stop loss at $88.50

Summary: Short UPST from ~$85.50, fair value $65, stop at $88.50; dangerously overvalued.

$UPST ~$77 now  🤑
#SupDup #FastMoney

https://t.co/eJZ5UEwoH4


Summary: Both AXON and DGLY will benefit from Trump-era law enforcement funding and support.

$AXON & $DGLY both will benefit from Trump administration's support and funding for Law Enforcement & Security imo
#SupDup


Summary: Buy CING on dips at $4.55 or lower.

$CING $4.55 or lower = Good chance to add more on dips imo.
#SupDup


Summary: Adding to long position in CING at $4.60.

$CING $4.60 - Time for me to buy more
#SupDup


Summary: Buying VCIG at $0.185 for short-term/near-term trade.


Summary: Bullish on SMCI's one-stop liquid cooling and server infrastructure solution as a positive catalyst.

$SMCI - NEWS !! This is awesome imo
"At Supermicro, we're able to offer a complete one-stop solution that includes servers, racks, networking, liquid cooling components, and liquid cooling towers, speeding up the time to deployment and resulting in higher quality and reliability across the entire infrastructure, enabling customers faster time to results. Up to 90% of the server generated heat is removed with the liquid cooling solution, saving significant amounts of energy and enabling higher compute performance."
#SupDup

https://t.co/ItbIn0XQlC


Summary: SMCI expected to rise strongly in both near-term and long-term.

@chelsRK I see $SMCI rising strongly in NT & LT imo

Okay last stock before bed. $smci on the watchlist could be yugggggeeeeee


Summary: Building a large long position in CING on dips for near-term and long-term.

$CING ~$6 - Adding more on dips. Building a large long position for NT & LT
#SupDup


Summary: SMCI will reach $100+ in a couple years as DOJ/accounting concerns fade and are forgotten.

Possibly but I believe the sales would not be directly meaning there was a foreign intermediatory party that purchased and resold to banned entities/country(ies). Irrespective the worst that will happen is $SMCI will be fined like $10 mln to $150 mln, co will do a blame game and fire a few senior leaders perhaps CFO and within a couple years from now every one will forget and stock will be $100+ imo

@SuperDuperInvst Surely these numbers pass muster considering all the scrutiny.  Makes me think the DOJ stuff is unrelated to accounting more to do with russia/china business.


Summary: Author predicts SMCI will rise sharply over the long term.

$CYBR $285 now UP ~700%, sometimes patience pays off very well with a well managed company that is on growth trajectory.
$SMCI will rise sharply too in LT imo
#SupDup

$CYBR $41.85 = GREAT LONG TERM #Buy
#CyberSecurity leader with most Fortune 500 companies as Clients
#Hack Protection
#CyberArk target $65


Summary: Bullish on MBIO and ALLR as tomorrow's trading plays.

@TopStockAlerts1 Tomorrow's plays $MBIO & $ALLR imo


Summary: Flags ALLR, KPRX, CING as undervalued acquisition targets/gems vs Mariana Oncology's $1.75B NVS deal.

Mariana Oncology with just pre clinical drug in pipeline got acquired by #Novartis $NVS for a total deal value of $1.75 billion   😍
Compare this with pipelines, current company values & potentials for my recently shown gems $ALLR $KPRX $CING imo
#SupDup

https://t.co/Hwu449cAAN


Summary: Still long VCIG and plans to add more after CEO raised stake to 27%+.

$VCIG - I showed it at $0.19 and it went to $0.29 rising 25+% at one point quickly. Stocks go up and down all the time which is why I keep reminding to lock some or all of the gains that makes you happy. Most Mutual funds barely make 10% in 10 yrs remember that. I still own the stocks and have plans to add more after seeing CEO increased his stake to 27+% as seen from last PR imo


Summary: Still holds a large position; expects VCIG to rally.

@fuzzyramm I still own a large qty. It will have its day imo

@SuperDuperInvst what about $VCIG ? Will it keep dipping?


Summary: Author is actively buying CETX at $0.30 as a new long trade idea targeting multi-bagger returns.

$GNPX $1.90+ rn - HALTED again, UP 350% so far since I showed you all earlier this morning  🤑
$GRI - I showed you at $0.47 - Went up 400% in a day  🤑
$CETX $0.30 - My new long trade idea, I am buying.
This is your home to finding MULTI BAGGERS imo  💰
#SupDup #FastMoney


Summary: Long CING and CINGW; expects both to be much higher in near and long term, analogizing to LUNR/LUNRW spikes.

IF you missed out on $LUNR and $LUNRW triple digit quick spikes  🔥  🚀, don't miss out on $CING $5 and $CINGW $0.06 because both of them should be much much higher in NT & LT imo.
#SupDup


Summary: Expects an FDA-related press release within days, implying near-term bullish catalyst.

$MBIO $0.33 - Within next few days, I am expecting a PR that will have word FDA imo  😉
#SupDup


Summary: Shorting AMD at $152.50+ short-term after rally from $132 to $152+.

$AMD - Starting to short at $152.50+ for ST on this recent rally from $132 to $152+ imo
#SupDup


Summary: Buy GNLX at ~$2, target $5+ over 3 years for 100%+ returns.

$GNLX $2 - Buy 100 or more shares if you like it and can afford. Forget for 3 years and set a good till cancel limit sell order at $5. I am 99% sure you will see 100+% returns on this one in LT imo
#SupDup


Summary: Argues SMCI selloff is massively overdone relative to the potential scale of accounting irregularities; implicitly bullish at current levels.

$SMCI - Now I feel like there is some accounting manipulations for sure given E & Y resignation. I am starting to believe they indeed cooked the books somewhat. But as I said in the past co could have inflated their sales by max of 10% of course any such corporate wrong doing is illegal & unethical but company's stock has had $15 bln wiped out from market cap (Drop from $125 to $31 split adjusted) that's 10+ times of perhaps <$1 bln of inflated sales imo.
#SupDup

@SuperDuperInvst You think SMCI is cooked after EY dropped them as their auditor?


Summary: Bullish SMCI near- and long-term; great quarter, expects it to trade way higher despite volatility.

@colin_gladman $SMCI - Having a great qtr so I am bullish but as I have repeatedly mentioned to my followers, it will remain highly volatile with wild swings in both direction. But in NT & LT is will be way higher than it is today imo

$SMCI

See a lot of people liking this name.  Personally looking at it as retesting its support from the wedge breakdown.

Would be very cautious here.  Needs to look good over 650-670 IMO.  Best case it’s like the $QQQ liquidity sweep from last summer (also pictured)

A lot https://t.co/OSOP7T6iIE


Summary: Considering buying DJT tomorrow if it dips to $21–$25 range for a short-to-near-term trade.

$DJT ~$26 rn - Went up to ~$55 a week ago. But since yesterday the stock has seen selloff even with #Trump winning the Presidential election. I am thinking of buying tomorrow IF I see it in $21 - $25 range for DT/ST/NT.
#SupDup


Summary: Bullish CING short-term on upcoming FDA food-effect study data readout expected by end of 2024.

$CING - ST catalyst imo 👇
In September, Cingulate commenced its final FDA-required study, which is a food effect study, for CTx-1301. A data readout from the study is expected by the end of 2024.
#SupDup


Summary: Expecting NVDA to spike to $134–$142 post earnings from ~$126.

$NVDA ~$126 - I am expecting spike to $134 - $142 post ER imo. Lets see what happens !
#SupDup


Summary: Bullish SMCI on 3-year horizon; calls current ~$25 price dirt cheap and expects significant upside.

$SMCI - I can afford to lose $100k and be completely fine so I am not worried taking risk. No pain NO GAIN. In 3 years this will be very different and many may regret not loading up when stock was dirt cheap at $25's or even cheaper if this drops lower imo.
Those that took risk with $CVNA we all know what happened.
#SupDup

https://t.co/MyVrgfJPFK


Buying $ALLR float 1.4 mln shares for ST, NT but mostly LT as I see both companies valuation rise substantially over the time. This seems like a ground floor opportunity making both SCREAMING BUYS

Summary: Buying ALLR and KPRX as long-term ground-floor opportunities; expects substantial valuation rise, calls both screaming buys.

Buying $ALLR float 1.4 mln shares  & $KPRX 1.36 mln shares for ST, NT but mostly LT as I see both companies valuation rise substantially over the time. This seems like a ground floor opportunity making both SCREAMING BUYS for investors with patience imo
#SupDup


Buying $KPRX 1.36 mln shares for ST, NT but mostly LT as I see both companies valuation rise substantially over the time. This seems like a ground floor opportunity making both SCREAMING BUYS


Summary: Long GNPX, adding to position; expects a heavy spike similar to GRI.

$GNPX - Bought $0.47 - $0.52 and adding more, it could possibly spike heavily just like $GRI imo
#SupDup


Summary: Expects SMCI to reach $650–$700 range next week from current ~$617.

$SMCI $617 - We could likely see it in $650 - $700 range next week imo
#SupDup


Summary: Sell/short DRUG at $47; expects heavy drop within weeks despite possible brief near-term bounce.

$DRUG $47 rn = SELL SELL SELL or Short if you can.
May be it will rise somewhat for a day or so but in few weeks it will drop heavily imo
#SupDup


Summary: Author's 'business as usual' comment implies continued bullish stance on SMCI amid new X14 server product preview.

$SMCI - NEWS ! Business seems as usual at co imo
Supermicro Previews New Max Performance Intel-based X14 Servers for AI, HPC, and Critical Enterprise Workload

SAN JOSE, Calif., Aug. 28, 2024 /PRNewswire/ -- Supermicro, Inc. (NASDAQ:      SMCI) a Total IT Solution Provider for AI/ML, HPC, Cloud, Storage, and      5G/Edge, is previewing new, completely re-designed X14 server platforms      which will leverage next-generation technologies to maximize performance      for compute-intensive workloads and applications. Building on the success      of Supermicro's efficiency-optimized X14 servers that launched in June      2024, the new systems feature significant upgrades across the board,      supporting a never-before-seen 256 performance cores (P-cores) in a single      node, memory support up for MRDIMMs at 8800MT/s, and compatibility with      next-generation SXM, OAM, and PCIe GPUs. This combination can drastically      accelerate AI and compute as well as significantly reduce the time and      cost of large-scale AI training, high-performance computing, and complex      data analytics tasks. Approved customers can secure early access to      complete, full-production systems via Supermicro's Early Ship Program or      for remote testing with Supermicro JumpStart.

"We continue to add      to our already comprehensive Data Center Building Block solutions with      these new platforms, which will offer unprecedented performance, and new      advanced features," said Charles Liang, president and CEO of Supermicro.      "Supermicro is ready to deliver these high-performance solutions at      rack-scale with the industry's most comprehensive direct-to-chip liquid      cooled, total rack integration services, and a global manufacturing      capacity of up to 5,000 racks per month including 1,350 liquid cooled      racks. With our worldwide manufacturing capabilities, we can deliver fully      optimized solutions which accelerate our time-to-delivery like never      before, while also reducing TCO."

Click here for more      information.

These new X14 systems feature completely re-designed      architectures including new 10U and multi-node form factors to enable      support for next-generation GPUs and higher CPU densities, updated memory      slot configurations with 12 memory channels per CPU and new MRDIMMs which      provide up to 37% better memory performance compared to DDR5-6400 DIMMS.      In addition, upgraded storage interfaces will support higher drive      densities, and more systems with liquid cooling integrated directly into      the server architecture.

The new additions to the Supermicro X14      family comprise more than ten new systems, several of which are completely      new architectures in three distinct, workload-specific categories:

--      GPU-optimized platforms designed for pure performance and enhanced thermal      capacity to support the highest-wattage GPUs. System architectures have      been built from the ground up for large-scale AI training, LLMs,      generative AI, 3D media, and virtualization applications. -- High      compute-density multi-nodes including SuperBlade(R) and the all-new      FlexTwin(TM), which leverage direct-to-chip liquid cooling to      significantly increase the number of performance cores in a standard rack      compared to previous generations of systems. -- Market-proven Hyper      rackmounts combine single or dual socket architectures with flexible I/O      and storage configurations in traditional form factors to help enterprises      and data centers scale up and out as their workloads evolve.

Supermicro      X14 performance-optimized systems will support the soon-to-be-released      Intel(R) Xeon(R) 6900 series processors with P-cores and will also offer      socket compatibility to support Intel Xeon 6900 series processors with      E-cores in Q1'25. This designed-in feature allows workload-optimized      systems for either performance-per-core or performance-per-watt.

"The      new Intel Xeon 6900 series processors with P-cores are our most powerful      ever, with more cores and exceptional memory bandwidth & I/O to achieve      new degrees of performance for AI and compute-intensive workloads," said      Ryan Tabrah, VP and GM of Xeon 6 at Intel. "Our continued partnership with      Supermicro will result in some of the industry's most powerful systems      that are ready to meet the ever-heightening demands of modern AI and      high-performance computing."

When configured with Intel Xeon      6900 series processors with P-cores, Supermicro systems support new FP16      instructions on the built-in Intel(R) AMX accelerator to further enhance      AI workload performance. These systems include 12 memory channels per CPU      with support for both DDR5-6400 and MRDIMMs up to 8800MT/s, CXL 2.0, and      feature more extensive support for high-density, industry-standard EDSFF      E1.S and E3.S NVMe drives.

Supermicro Liquid Cooling Solutions

Complementing      this expanded X14 product portfolio are Supermicro's rack-scale      integration and liquid cooling capabilities. With an industry-leading      global manufacturing capacity, extensive rack-scale integration and      testing facilities, and a comprehensive suite of management software      solutions, Supermicro designs, builds, tests, validates, and delivers      complete solutions at any scale in a matter of weeks.

In addition,      Supermicro offers a complete in-house developed liquid cooling solution      including cold plates for CPUs, GPUs and memory, Cooling Distribution      Units, Cooling Distribution Manifolds, hoses, connectors, and cooling      towers. Liquid cooling can be easily included in rack-level integrations      to further increase system efficiency, reduce instances of thermal      throttling, and lower both the TCO and Total Cost to Environment (TCE) of      data center deployments.

Upcoming Supermicro X14      performance-optimized systems include:

GPU-optimized -- The highest      performance Supermicro X14 systems designed for large-scale AI training,      large language models (LLMs), generative AI and HPC, and supporting eight      of the latest-generation SXM5 and SXM6 GPUs. These systems are available      in air-cooled or liquid-cooled configurations.

PCIe GPU -- Designed      for maximum GPU flexibility, supporting up to 10 double-width PCIe 5.0      accelerator cards in a thermally-optimized 5U chassis. These servers are      ideal for media, collaborative design, simulation, cloud gaming, and      virtualization workloads.

Intel(R) Gaudi(R) 3 AI Accelerators --      Supermicro also plans to deliver the industry's first AI server based on      the Intel Gaudi 3 accelerator hosted by Intel Xeon 6 processors. The      system is expected to increase efficiency and lower the cost of      large-scale AI model training and AI inferencing. The system features      eight Intel Gaudi 3 accelerators on an OAM universal baseboard, six      integrated OSFP ports for cost-effective scale-out networking, and an open      platform designed to use a community-based, open-source software stack,      requiring no software licensing costs.

SuperBlade(R) - Supermicro's      X14 6U high-performance, density-optimized, and energy-efficient      SuperBlade maximizes rack density, with up to 100 servers and 200 GPUs per      rack. Optimized for AI, HPC, and other compute-intensive workloads, each      node features air cooling or direct-to-chip liquid cooling to maximize      efficiency and achieve the lowest PUE with the best TCO, as well as      connectivity up to four integrated Ethernet switches with 100G uplinks and      front I/O supporting a range of flexible networking options up to 400G      InfiniBand or 400G Ethernet per node.

FlexTwin(TM) - The new      Supermicro X14 FlexTwin architecture is designed to provide maximum      compute power and density in a multi-node configuration with up to 24,576      performance cores in a 48U rack. Optimized for HPC and other      compute-intensive workloads, each node features direct-to-chip liquid      cooling only to maximize efficiency and reduce instances of CPU thermal      throttling, as well as HPC Low Latency front and rear I/O supporting a      range of flexible networking options up to 400G per node.

Hyper -      X14 Hyper is Supermicro's flagship rackmount platform designed to deliver      the highest performance for demanding AI, HPC, and enterprise      applications, with single or dual socket configurations supporting      double-width PCIe GPUs for maximum workload acceleration. Both air cooling      and direct-to-chip liquid cooling models are available to facilitate the      support of top-bin CPUs without thermal limitations and reduce data center      cooling costs while also increasing efficiency.

About Super Micro      Computer, Inc.

Supermicro (NASDAQ: SMCI) is a global leader in      Application-Optimized Total IT Solutions. Founded and operating in San      Jose, California, Supermicro is committed to delivering first to market      innovation for Enterprise, Cloud, AI, and 5G Telco/Edge IT Infrastructure.      We are a Total IT Solutions provider with server, AI, storage, IoT, switch      systems, software, and support services. Supermicro's motherboard, power,      and chassis design expertise further enable our development and      production, enabling next generation innovation from cloud to edge for our      global customers. Our products are designed and manufactured in-house (in      the US, Taiwan, and the Netherlands), leveraging global operations for      scale and efficiency and optimized to improve TCO and reduce environmental      impact (Green Computing). The award-winning portfolio of Server Building      Block Solutions(R) allows customers to optimize for their exact workload      and application by selecting from a broad family of systems built from our      flexible and reusable building blocks that support a comprehensive set of      form factors, processors, memory, GPUs, storage, networking, power, and      cooling solutions (air-conditioned, free air cooling or liquid cooling).


Summary: Long GNLX from under $2.15; near-term PT $5–$7, long-term $10+.

$GNLX <$2.15 - Don't missout on it, get in before big whales discover it and start loading up.
My NT PT is $5 - $7, LT $10+ imo
#SupDup


Summary: Long VCIG; $13M market cap seen as very attractive, fundamentals/outlook support at least $0.50 vs current $0.185; naked short squeeze catalyst.

$VCIG $0.185 - Current market cap of just $13 mln makes this very attractive buy, this stock should be trading at $0.50 at least based on its fundamentals and outlook. Remember this stock used to be $9.25+ just less than a year ago.
Its mostly naked short selling but eventually will be forced to square up their positions imo
#SupDup


Summary: Bullish CING on clear commercialization path for CTx-1301 targeting $20B ADHD market with full-day precision-release approach.

$CING - Clear path to commercialize CTx-1301, upon FDA approval, designed specifically to tackle the unmet needs of this $20 billion market by providing the first true, entire-active-day treatment for #ADHD with Precision Timed-Release approach imo
#SupDup


Summary: Long GRI Bio: market cap below cash, VERY undervalued, attractive buyout candidate with 500+ compounds and M&A activity in IPF space.

$GRI 0.77 - GRI Bio, Inc. is still VERY UNDERVALUED despite recent run up and small capital raise given its market cap is still <$3 mln whereas Cash on Hand is ~$6.75 mln.  Attractive buyout candidate in the active M&A happening in the sector of operation due to its promising drug development pipeline which can get expand from their library of 500+ proprietary compounds. Recent acquisitions in IPF (Idiopathic Pulmonary Fibrosis) have happened at much higher valuations as seen from  👇  imo
#SupDup


Buying slowly & steadily to someday sell at much higher prices. From all my DD, I find this company's valuation being overly UNDERVALUED. For investors with patience this will be a huge jackpot someday in future

Summary: Long GNLX at ~$2.15; former $30+ stock now overly undervalued per DD, with huge upside for patient investors.

$GNLX ~$2.15 - Buying slowly & steadily to someday sell at much higher prices.
This used to be $30+ stock within this last year. Nothing has changed other than more progress has been made by the mgmt on all fronts. From all my DD, I find this company's valuation being overly UNDERVALUED. For investors with patience this will be a huge jackpot someday in future imo
#SupDup


Summary: Bullish AAOI; author sees it under accumulation.

$AAOI - Under accumulation lately imo
#SupDup


Summary: Long CING; author says accumulate patiently for eventual explosive upside move.

Bring your gains from $LUNR  & $VVOS to $CING $5, You gonna thank me one day when its stock skyrockets just like the other 2.
Did you miss out on 200% to 300% quicks gains then start accumulating Cingulate (CING) stocks but only if you have some patience. One fine morning it will  🧨 🔥 🚀  imo
#SupDup


Summary: Buying VCIG at $0.19; sellers drying up signals bullish supply/demand setup.

$VCIG - Sellers drying, I barely got fill for 560 shares on my 200k buy order at $0.19
#SupDup


Summary: Holding SMCI long-term, hoping for $100+ in 3 years from current $24.

$SMCI $24 rn - Removing from my watch list for 3 years. Will keep what I own and forget. Hopefully after 3 years stock will be $100+  and not <$10  🤞
Now on you will not hear about this stock for 3 years from me. Please don't tell me anything about it even if stock rises on any huge news or falls more on bad news.
#SupDup


Summary: Long ASTS; bought dips below $25 as a day/swing trade.

$ASTS - Bought <$25 on dips to DT/ST
#SupDup


Summary: Bullish VCIG; author sees heavy accumulation driving slow, steady upward price move.

$VCIG - Under heavy accumulation inching higher slowly & steadily imo
#SupDup #PennyStock


Summary: Long SMCI; added on the dip, expects AI chip/server sector rally on NVDA earnings to lift it.

$SMCI $540+ rn, rising back again. Think guys - Hindenburg Research short sells the stock and puts out accounting and other allegations day before $NVDA ER. They know today was the best time to cover short prior to #Nvidia earnings which may cause a strong rally in #AI chips/servers sector.
What a smart move by Hindenburg but I am happy I got to add more even at much cheaper prices imo
#SupDup


Summary: Buying CING dips to sell higher on expected licensing deal announcement for ADHD drug US rights.

$CING ~$6.75 - Buying again on dips like I did on Friday to sell at higher prices upon announcement of licensing deal for its ADHD drug for US rights news imo
#SupDup


Summary: Bullish CETX at $0.33 on thin float and recent multi-million dollar contract wins; sees classic turnaround.

$CETX $0.33 - Was $2+ just 15 days ago.
Super thin float, Multi Million $ contract wins in last few weeks and more to come in ST/NT. Classic turnaround possible imo.
#SupDup

https://t.co/EdqZ8F8Le9


Summary: Added to MBIO long position at $0.30 for day/short/near-term trade.

$MBIO - Added more at $0.30 for DT/ST/NT
#SupDup


Summary: Long VVOS at $2.40; targets $5+ within 1 year for ~100% return.

$VVOS $2.40 - Time for me to buy more for ST, NT & LT.
This should be $5+ within 1 year providing 100% returns imo
#SupDup #SleepApnea #OSA #SRBD


Summary: Bought LUNR on dips at $6.85 for a short-term trade.

$LUNR - Bought some on dips at $6.85 for ST
#SupDup


Summary: Buying VCIG at $0.20 expecting to double quickly.

$LUNR $6+ & $LUNRW $1.45 rn, bringing some of my profits to $VCIG $0.20 to double money again quickly imo
#SupDup


Summary: Possible spike to $3+ this week on heavy after-hours buying.

$GNLX - Heavy buying in AHrs, watch for possible spike to $3 or higher this week imo
#SupDup


Summary: CING seen moving from $4.50 to $5+ next week.


Summary: Buying VCIG on dips at $0.19.


Summary: Adding to VCIG position on dips, prompted by CEO stock purchase news.

$VCIG $0.225 - Adding more on dips after seeing today's news of its CEO purchase.
#SupDup

https://t.co/EANCry8JNG


Summary: Long KPRX from $3.60 to $25+ long-term based on CFO presentation thesis.

$KPRX $3.60 - View this video of presentation by CFO from earlier this year. Watch till the end and you will know why I see this stock someday in LT at $25+ imo
#SupDup

https://t.co/bnsHRmXs8S